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A specific and sensitive radioimmunoassay for adrenomedullin has been developed. Half-maximal inhibition of binding of radioiodinated adre- 
nomedullin was observed at 4 fmol/tube. The radioimmunoassay recognized the entire adrenomedullin molecule and has little crossreactivity with 
adrenomedullin fragment peptides. Adrenomedullin-like immunoreactivity was found to circulate in human plasma at considerable concentration 
(3.3 + 0.39 fmol/ml). The immunoreactivity of adrenomedullin was eluted at almost the same position as synthetic adrenomedullin on gel-filtration 
chromatography and reverse-phase high-performance liquid chromatography, suggesting that circulating adrenomedullin recognized by the present 
radioimmunoassay is identical or very similar to authentic adrenomedullin. Plasma immunoreactive adrenomedullin signiticantly increased in patients 
with hypertension, with a progressive rise proportionate to disease severity. 
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1. Introduction 
Adrenomedullin (AM) is a hypotensive peptide re- 
cently discovered by monitoring the elevating activity of 
platelet CAMP in human pheochromocytoma [l]. The 
peptide, consisting of 52 amino acids, has one intramol- 
ecular disulfide bond and shows slight homology with 
the calcitonin gene-related peptide. AM elicited a potent 
and long lasting hypotensive ffect when injected intrave- 
nously in anesthetized rats [2]. Sequence analysis of 
cloned human AM cDNA showed that human AM pre- 
cursor is 185 amino acids in length, including a putative 
signal peptide [3]. Studies of regional distribution in 
human tissue showed that immunoreactive (ir)-AM was 
abundant in the normal adrenal medulla as well as in 
pheochromocytoma tissue [1,4]. Ir-AM is present in cir- 
culating blood in considerable concentration [I]. These 
findings indicate that AM may be a new hormone partic- 
ipating in circulation control. 
In order to investigate AM’s physiological and clinical 
roles, it is essential to establish a radioimmunoassay 
(RIA) to measure its plasma concentration. In the pres- 
ent study, we established a highly sensitive and specific 
RIA for AM. With this RIA, we examined the concen- 
tration and molecular form of ii--AM in human plasma. 
*Corresponding author. Fax: (8 1) (985) 85 6596. 
2. Materials and methods 
2.1. Chemicals 
Human AM, AM[13-521, AM[40-521, AM[l-131 and AM[13-311 
were prepared by the solid phase method. Bovine serum albumin (BSA, 
Sigma) for RIA-was pretreated with 5 mM N-ethyhnaleimide for 24 h 
at room temperature and was purified by the ammonium sulfate precip- 
itation method [5]. 
2.2. Preparation of antiserum for AM 
Synthetic AM solution prepared above was emulsified with an equal 
volume of Freund’s complete adjuvant, and used for immunizing New 
Zealand white rabbits by subcutaneous injection at multiple sites in the 
interscapulovertebral egion. 
2.3. Radioiodination 
AM (10 ,ug) in 25 ~1 of 0.4 M sodium acetate buffer @H 5.6) was 
introduced into a tube followed by the addition of Nau51 (1.0 mCi/ 
10 ,ul, Amersham). Lactoperoxidase (Calbiochem: 600 ng/lO pl of 
0.1 M sodium acetate, pH 5.6) and HrOs (70 ng/5 ~1 of water) were 
added to the reaction tube. After standing for 15 min at 3O”C, H,Oa 
(100 ng/5 ~1 of water) was added to the tube, which was left for another 
10 min at 3O’C. Immediately after reaction, the mixture was submitted 
to reverse-phase high-performance liquid chromatography (HPLC), 
and monoiodinated AM was purified and used as a tracer. 
2.4. Procedures for RIA 
The incubation buffer for RIA was 0.05 M sodium phosphate buffer 
@H 7.4), containing 0.5% BSA, 0.5% Triton X-100,0.08 M NaCI, 0.025 
M EDTA 2Na, 0.05% NaN,, and Trasylol 500 K.IU/ml. A disposable 
plastic tube (10 x 75 mm) was used for assay. All assay procedures were 
performed at 4°C. The standard AM or the unknown sample (100 ~1) 
was incubated with anti-AM antiserum diluent (200 ~1) for 12 h, then 
the tracer solution (18,000-20,000 cpm in 100 ~1) was added. After 
incubation for 36 h, anti-rabbit IgG goat serum diluent (100 ~1) was 
added. After standing for 24 h, the tubes were centrifuged at 2,000 x g 
for 30 min at 4°C and radioactivity of the precipitate was measured in 
an Aloka ARC-600 gamma counter. 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00203-g 
K Kitamura et al. IFEBS Letters 341 (1994) 288-290 289 
2.5. Preparation of plasma sample 
Human plasma samples were taken with EDTA 2Na (1 mg/ml) and 
Trasylol(500 KIU/ml). Plasma was separated by centrifugation at 4°C 
and stored at -30°C until use. Five ml of plasma was acidified with 60 
ul of 1 M HCl and diluted with 5 ml of saline and then loaded onto a 
‘Sep-Pak Cl8 cartridge (Waters) which was preequilibrated with saline. 
After washing with 5 ml of saline and 5 ml of 20% acetonitrile contain- 
ing 0.1% trifluoroacetic acid (TFA), the adsorbed materials were eluted 
with 4 ml of 50% acetonitrile containing 0.1% TFA. The eluate was 
lyophilized, and the residual materials were dissolved in RIA buffer and 
the clear solution was submitted to RIA. 
2.6. Statistics 
Values are given as mean + S.E.M. Statistical analysis was carried 
out using one-way analysis of variance with Bonferroni correction [6] 
for multiple group comparisons. 
3. Results and discussion 
3.1. RIA for AM 
The antiserum to AM recognized the peptide with high 
affinity at a final dilution of 1:24,000. As shown in Fig. 
1, half-maximum inhibition of radioiodinated ligand 
binding by AM was observed at 4 fmol/tube. From 0.5 
to 32 fmol/tube of AM was measurable by this RIA 
system. The intra- and inter-assay coefficients of vari- 
ance were 5% and 8%, respectively. This RIA had 100% 
crossreactivity with the Met sulfoxide form of AM, but 
had 2% and 0.5% crossreactivity with AM[l3-521 and 
AM[40-521, respectively. It had less than 0.01% 
crossreactivity with AM[l-121 and AM[13-311. These 
data indicate that this antibody recognizes the entire AM 
molecule. 
The high specificity and sensitivity of the RIA for AM 
prepared above enabled us to determine the AM plasma 
concentration in healthy volunteers and patients with 
several disorders. However the plasma sample had to be 
treated with a Sep-Pak C- 18 cartridge (Waters), since the 
plasma concentration of ir-AM in human plasma was 
found to be low. 
Prior to measurement of ir-AM, the efficiency of ex- 
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Fig. 1. Inhibition of [i*‘I]AM binding to antiserum against AM. (o), 
AM; (m), AM[13-521; (o), AM[40-521; 0, AM[l-121; (n), AM[13- 
311. The dilution curves of plasma sample (0) are roughly parallel to 
those of standard AM. 
Fig. 2. Sephadex G-50 gel-filtration of human plasma sample moni- 
tored by RIA for AM. Sample: 100 ml of human plasma treated with 
Sep-Pak Cl8 cartridge as described in the text. Column size: 1.5 x 100 
cm. Fraction size: 4.0 ml/tube. Elution butfer: 1 M CHJOOH. Arrows 
indicate elution positions of: (a) void volume; (b) AM; (c) aprotinin, (d) 
NaCl. 
traction and reliability of RIA procedures were validated 
by the following experiments with normal human 
plasma: 
(1) [12’I’JAM or synthetic AM added to the plasma sample 
before extraction were reproducibly found to be more 
than 90% recovered when it was treated with a Sep-Pak 
C- 18 cartridge. 
(2) Dilution of RIA sample, prepared as described in 
section 2, yielded competition curves that were roughly 
parallel to the standard curves of AM as shown in 
Fig. 1. 
(3) An appropriate amount of cold synthetic AM added 
to the RIA sample proved to be precisely determined by 
the present RIA. 
3.2. Characterization of ir-AM in human plasma 
Prior to assay of ii--AM in human plasma, the im- 
munoreactive species present in human plasma were 
characterized by the following experiments. One hun- 
dred ml of healthy human plasma was treated with a 
Sep-Pak Cl8 cartridge as described in section 2. The 
sample thus obtained was submitted to gel titration on 
a Sephadex G-50 column, and monitored by RIA for 
AM (Fig. 2). Only a single major peak of ir-AM was 
observed at a position almost identical with that of au- 
thentic human AM. The ir-AM fraction thus obtained 
was submitted to HPLC on a reverse phase column that 
was also monitored by RIA for AM. As seen in Fig. 3, 
one major peak of ir-AM, possessing more than 90% of 
the total immunoreactivity, emerged at a position almost 
identical with that of authentic human AM. These data 
indicate that ir-AM in human plasma, as monitored by 
the present RIA, is identical or very similar to authentic 
AM. 
290 L Kitamura et al. IFEBS Letters 341 (1994) 288-290 
3.3. Ir-AM concentration in plasma of hypertensive 
patients 
The high specificity and sensitivity of the RIA for AM 
enabled us to determine the plasma concentration of 
ir-AM in healthy volunteers and in patients with several 
disorders. In the present study, blood samples were 
drawn in the early morning from eight healthy volun- 
teers. Furthermore, as a pathological condition in which 
plasma AM level might be increased, essential hyperten- 
sion was focused, and blood samples were obtained from 
19 patients with hypertension. The patients were 
grouped according to the World Health Organization 
(WHO) classification on the basis of their clinical charac- 
teristics. As shown in Fig. 4, in normal subjects the mean 
level of AM immunoreactivity in peripheral plasma was 
3.3 f 0.39 fmol per mililiter. The plasma ir-AM concen- 
tration in severe hypertension (WHO stage III) patients 
(8.39 + 0.39) was significantly (P < 0.05) higher than that 
in normal subjects and mild hypertension subjects (4.66 
& 0.59). In addition, the mean plasma ir-AM concentra- 
tion in mild and moderate hypertension (WHO stage I 
and II) showed a tendency to increase in comparison to 
that in normal subjects. Thus, the augmentation of 
plasma ii--AM in patients with hypertension seems to be 
progressive, proportionate to disease severity. 
We have already shown [ 1,2] that AM elicited a potent 
and long lasting hypotensive activity which is compara- 
ble to that of CGRP, one of the strongest vasorelaxants 
known [7]. The potent vasodilator effect of AM has re- 
cently been shown to be a causative hypotensive mecha- 
nism in anesthetized rats [2,8]. Therefore, whatever the 
mechanism for the increase of AM in hypertension, hy- 
potensive and vasodilator effects of AM should be ex- 
pected to counteract with arteriolar vasoconstriction 
found in hypertension and may therefore be of benefit 
in vivo. 
We have already shown that a high level of AM 
mRNA, found in lung, ventricle and kidney, as well as 
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Fig. 4. Immunoreactive AM in plasma of normotensive (NT) volun- 
teers and hypertensive patients. Patients were grouped according to 
WHO stages I-III on basis of clinical characteristics. Number of sam- 
ples: NT, 8; WHO I, 6; WHO II, 8; WHO III, 5. *P < 0.05 vs. NT and 
WHO I. 
in adrenal medulla, may contribute to ir-AM in human 
plasma [3]. Although the sauce of circulating AM re- 
mains obscure, the present data suggest hat AM is a 
circulating hormone participating in circulation control. 
In addition, measurement of the plasma concentration of 
AM by the present RIA will help to clarify the pa- 
thophysiological role of AM in cardiovascular diseases. 
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Fig. 3. Reverse-phase HPLC of plasma sample monitored by RIA for 
AM. Sample, half of fraction 35-38 in Fig. 2; Column, TSK ODS SIL 
120 A (4.6 x 150 mm, Tosoh); solvent system, H,O/CH,CN/lO%TFA 
= (I) 90: 10:1, (II) 40:60:1 (v/v). Linear gradient from (I) to (II) for 60 
min. Flow rate: 1 ml/min. The arrow indicates the elution position of 
AM. 
